Manpreet Singh, MD
Interventional Cardiology · Baton Rouge, LANPI 1902066848
Payments from drug & device makers
Across 228 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$443
- Novo Nordisk$399
- Novartis$381
- Johnson & Johnson$381
- Abiomed$295
- Abbott$293
- plus $3K from 31 others
What the payments were for
- Food & beverage$4,717100%
- Other$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 26 | $443 |
| Novo Nordisk | 21 | $399 |
| Novartis | 27 | $381 |
| Johnson & Johnson | 20 | $381 |
| Abiomed | 3 | $295 |
| Abbott | 11 | $293 |
| Medtronic(2 entities) | 4 | $235 |
| Shockwave Medical, Inc | 2 | $219 |
| Amgen | 13 | $204 |
| Pfizer | 10 | $204 |
| Esperion Therapeutics, Inc. | 12 | $181 |
| Edwards Lifesciences | 6 | $161 |
| Bayer | 10 | $159 |
| E.r. Squibb & Sons, L.L.C. | 9 | $150 |
| Boston Scientific | 3 | $142 |
| Sanofi-aventis U.S. LLC | 6 | $89 |
| AstraZeneca | 6 | $76 |
| Regeneron Healthcare Solutions, Inc. | 4 | $68 |
| Angiodynamics, Inc. | 1 | $65 |
| Actelion Pharmaceuticals US, Inc. | 4 | $64 |
| Chiesi USA, Inc. | 4 | $60 |
| Baxter Healthcare | 2 | $60 |
| Lundbeck LLC | 4 | $55 |
| Boehringer Ingelheim | 3 | $46 |
| Philips North America LLC | 2 | $43 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Akcea Therapeutics, Inc. | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Cordis US CORP. | 1 | $20 |
| Exact Sciences | 1 | $16 |
| Celonova Biosciences, Inc. | 1 | $16 |
| Terumo Medical Corporation | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $13 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,734 in reported general payments places this provider in the 25th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 71 | $67,074 |
| WegovySemaglutide | 45 | $66,815 |
| XareltoRivaroxaban | 64 | $63,477 |
| JardianceEmpagliflozin | 61 | $58,543 |
| Repatha SureclickEvolocumab | 73 | $57,522 |
| OzempicSemaglutide | 34 | $45,875 |
| Droxidopa | 17 | $39,903 |
| EntrestoSacubitril/Valsartan | 36 | $38,675 |
| MounjaroTirzepatide | 27 | $37,103 |
| FarxigaDapagliflozin Propanediol | 38 | $23,610 |
| NexletolBempedoic Acid | 20 | $13,186 |
| Praluent PenAlirocumab | 11 | $9,244 |
| Olmesartan Medoxomil | 145 | $1,898 |
| Metoprolol Succinate | 138 | $1,486 |
| Ondansetron Hcl | 114 | $1,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskWegovy, Ozempic | $399 | $112,69079 claims |
| PfizerEliquis | $204 | $67,07471 claims |
| Johnson & JohnsonXarelto | $381 | $63,47764 claims |
| Boehringer IngelheimJardiance | $46 | $58,54361 claims |
| NovartisEntresto | $381 | $38,67536 claims |
| AstraZenecaFarxiga | $76 | $23,61038 claims |
| Esperion Therapeutics, Inc.Nexletol | $181 | $13,18620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Baton Rouge
- Denzil MoraesBaton Rouge$1.4M
- Jorge CastellanosBaton Rouge$561K
- Venkata GadiBaton Rouge$132K
- Steven KelleyBaton Rouge$116K
- Andrew ReesBaton Rouge$95K
- Garland GreenBaton Rouge$37K
- Harold HelmkeBaton Rouge$32K
- Lance LamotteBaton Rouge$24K
- Craig WalkerHouma$5.5M
- Naseem JaffraniAlexandria$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.